Cheshire-based Alexion Pharmaceuticals Inc. said today Canadian health regulators have approved the use of its branded therapy to treat a rare and deadly blood disorder.
Alexion’s Soliris drug therapy has been used in U.S. hospitals since it was first approved by the Food and Drug Administration in 2007 to treat patients stricken with the chronic disorder that destroys red blood cells. It also was cleared in 2007 for use in European patients.
Soliris is the first drug approved in Canada to treat the disorder, Alexion said.
At 11 a.m., Alexion shares traded at $36.51, up 68 cents, or 1.9 percent.
